Tacrolimus + Mycophenolate Mofetil + Methylprednisolone or equivalent + Prednisone
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation, Kidney Failure, Chronic, Renal Insufficiency, Chronic
Trial Timeline
May 1, 2007 → Oct 1, 2008
NCT ID
NCT00717379About Tacrolimus + Mycophenolate Mofetil + Methylprednisolone or equivalent + Prednisone
Tacrolimus + Mycophenolate Mofetil + Methylprednisolone or equivalent + Prednisone is a approved stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00717379. Target conditions include Kidney Transplantation, Kidney Failure, Chronic, Renal Insufficiency, Chronic.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00717379 | Approved | Completed |
Competing Products
20 competing products in Kidney Transplantation